Rock Springs Capital CRVO Position
ExitedRock Springs Capital exited their position in CervoMed Inc. (CRVO) in Q4 2023, after holding the stock for 2 quarters.
The position was first reported in Q3 2023 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds CRVO.
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.
Full company profile →Short Interest
4.2%
2.9 days to cover
Rock Springs Capital CRVO Position History
Frequently Asked Questions
Does Rock Springs Capital own CRVO?
No. Rock Springs Capital exited their position in CervoMed Inc. (CRVO) in Q4 2023. They previously held the stock for 2 quarters.
How many hedge funds own CRVO?
1 specialist biotech hedge fund currently holds CRVO, including RA Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy CRVO?
Rock Springs Capital's position in CRVO was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's CRVO position increasing or decreasing?
Rock Springs Capital completely exited their CRVO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CRVOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →